Shares of Chimerix Inc (NASDAQ:CMRX) have been given a consensus recommendation of “Hold” by the six research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $7.67.
Several analysts have recently weighed in on CMRX shares. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Friday, November 10th. ValuEngine downgraded Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. HC Wainwright initiated coverage on Chimerix in a report on Friday, February 2nd. They issued a “buy” rating and a $10.00 price objective for the company. Finally, JPMorgan Chase & Co. downgraded Chimerix from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th.
Chimerix (NASDAQ:CMRX) traded up $0.07 during trading hours on Wednesday, hitting $5.02. The stock had a trading volume of 251,200 shares, compared to its average volume of 271,088. Chimerix has a fifty-two week low of $4.17 and a fifty-two week high of $6.64. The company has a market capitalization of $236.58, a P/E ratio of -3.51 and a beta of 1.42.
Several hedge funds have recently added to or reduced their stakes in CMRX. Prosight Management LP bought a new stake in shares of Chimerix in the fourth quarter valued at about $6,846,000. ArrowMark Colorado Holdings LLC raised its holdings in shares of Chimerix by 58.3% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,707,986 shares of the biopharmaceutical company’s stock valued at $12,538,000 after acquiring an additional 996,936 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Chimerix by 20.7% in the fourth quarter. BlackRock Inc. now owns 3,530,729 shares of the biopharmaceutical company’s stock valued at $16,348,000 after acquiring an additional 605,075 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Chimerix by 38.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,448,250 shares of the biopharmaceutical company’s stock valued at $7,893,000 after acquiring an additional 404,914 shares in the last quarter. Finally, Ascend Capital LLC raised its holdings in shares of Chimerix by 96.9% in the fourth quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 344,311 shares in the last quarter. Hedge funds and other institutional investors own 72.69% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Chimerix Inc (CMRX) Receives Average Recommendation of “Hold” from Analysts” was first posted by Week Herald and is the property of of Week Herald. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://weekherald.com/2018/03/14/chimerix-inc-cmrx-receives-average-recommendation-of-hold-from-analysts.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.